Monograph Details
|
|
Poisoning & Drug Dependence
> Addiction/dependence
|
|
VIVITROL |
| Manufacturer |
|
Cephalon, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Opioid antagonist. |
| Generic Name |
|
Naltrexone 380mg/vial; ext-rel susp for IM inj. |
| Indications |
|
Alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting, in conjunction with psychosocial support (eg, counseling or group therapy). |
| Children |
|
Not recommended. |
| Adults |
|
Give by IM inj into alternating buttocks. 380mg once every 4 weeks. |
| Contraindications |
|
Concomitant opioids. Current physiologic opioid dependence. Acute opiate withdrawal. Failed naloxone challenge test. Positive urine test for opioids. Acute hepatitis. Liver failure. |
| Precautions |
|
Active liver disease (monitor closely). Consider naloxone challenge test before treating to exclude recent (7–10 days) opioid use. Discontinue if hepatitis develops. Moderate to severe renal dysfunction. Coagulation disorders. Follow-up if respiratory symptoms occur. Monitor for depression and/or suicidality. Advise patient of reduced post-treatment opioid tolerance and of danger of attempting to overcome opioid blockade; advise use of medication alert documentation. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
See Contraindications. Antagonizes opioids (eg, antitussives, antidiarrheals, analgesics); use benzodiazepines, non-opioids, and/or anesthesia if pain management is necessary. May interfere with urine opioid tests. |
| Adverse Reactions |
|
GI upset, fatigue, headache, dizziness, inj site reactions (may be serious, follow-up if no improvement after 1 month); allergic (eosinophilic) pneumonia (rare). |
| How Supplied |
|
Vial—1 (w. supplies) |
|
|
|
|
